Journal ArticleDOI
Activity of clinafloxacin, trovafloxacin, quinupristin/dalfopristin, and other antimicrobial agents versus Staphylococcus aureus isolates with reduced susceptibility to vancomycin
Michael A. Cohen,M D Huband +1 more
Reads0
Chats0
TLDR
ClinafloxacIn testing here by broth microdilution according to NCCLS guidelines and applying vancomycin breakpoint criteria, two of three strains were susceptible to vancomYcin rather than intermediate (MICs at 8 micrograms/mL) as previously reported by other laboratories.About:
This article is published in Diagnostic Microbiology and Infectious Disease.The article was published on 1999-01-01. It has received 19 citations till now. The article focuses on the topics: Dalfopristin & Quinupristin/dalfopristin.read more
Citations
More filters
Journal ArticleDOI
Antimicrobial efficacy of riboflavin/UVA combination (365 nm) in vitro for bacterial and fungal isolates: a potential new treatment for infectious keratitis.
Suy Anne R. Martins,Juan Castro Combs,Guillermo Noguera,Walter Camacho,Priscila Wittmann,Rhonda Walther,Marisol Cano,James D. Dick,Ashley Behrens +8 more
TL;DR: Riboflavin/UVA was effective against SA, SE, PA, MRSA, MDRPA, and DRSP, but was ineffective on CA and has the potential for use in treatment of microbial keratitis in the future.
Journal ArticleDOI
Quinupristin-Dalfopristin and Linezolid: Evidence and Opinion
TL;DR: Quinupristin-dalfopristin and linezolid demonstrate in vitro activity against a wide range of gram-positive bacteria, including many isolates resistant to earlier antimicrobials.
Journal ArticleDOI
Treatment of methicillin-resistant Staphylococcus aureus infections with quinupristin–dalfopristin in patients intolerant of or failing prior therapy
Richard H. Drew,John R. Perfect,Latha Srinath,Elisabeth Kurkimilis,Michael Dowzicky,George H. Talbot +5 more
TL;DR: Quinupristin-dalfopristin should be considered as a treatment option for infections caused by MRSA, especially in patients intolerant of or failing alternate therapy.
Journal ArticleDOI
Emerging options for treatment of invasive, multidrug-resistant Staphylococcus aureus infections.
TL;DR: Treatment options for MRSA including linezolid, quinupristin‐dalfopristin, daptomycin, and tigecycline are being reexplored in the setting of increasing concern over MRSA acquired in the community setting.
Journal ArticleDOI
Clinafloxacin versus Piperacillin-Tazobactam in Treatment of Patients with Severe Skin and Soft Tissue Infections
TL;DR: Clinafloxacin monotherapy was equivalent in effectiveness to therapy with piperacillin-tazobactam plus optional vancomycin in the treatment of hospitalized patients with severe SSTIs, although no differences were statistically significant.
References
More filters
Journal ArticleDOI
Methicillin-resistant Staphylococcus aureus clinical strain with reduced vancomycin susceptibility.
TL;DR: Therapy was resumed with the com -bination of arbekacin and ampicillin/sulbactam which has been shown to have synergic activity against MRSA.
Journal ArticleDOI
Dissemination in Japanese hospitals of strains of Staphylococcus aureus heterogeneously resistant to vancomycin
Keiichi Hiramatsu,Nanae Aritaka,Hideaki Hanaki,Shiori Kawasaki,Yasuyuki Hosoda,Satoshi Hori,Yoshinosuke Fukuchi,Intetsu Kobayashi +7 more
TL;DR: Heterogeneously resistant VRSA was found in hospitals throughout Japan, which could explain, at least partly, the frequent therapeutic failure of MRSA infection with vancomycin in Japan.
Journal ArticleDOI
Co-transfer of vancomycin and other resistance genes from Enterococcus faecalis NCTC 12201 to Staphylococcus aureus
TL;DR: Conjugative transfer, in the apparent absence of plasmid DNA, of high-level vancomycin resistance from Enterococcus faecalis NCTC 12201 to Staphylococcus aureus B111 has been demonstrated and transfer of erythromycin and of chloramphenicol resistance has been achieved.
Journal ArticleDOI
Characterization of Staphylococci with Reduced Susceptibilities to Vancomycin and Other Glycopeptides
Fred C. Tenover,Michael V. Lancaster,B C Hill,Christine D. Steward,Sheila A. Stocker,G A Hancock,Caroline M. O'Hara,Nancye C. Clark,Keiichi Hiramatsu +8 more
TL;DR: B strains of staphylococci with reduced susceptibility to glycopeptides, such as vancomycin, are best detected in the laboratory by nonautomated quantitative tests incubated for a full 24 h.